

## SHORT-ACTING OPIOID ANALGESICS PRIOR AUTHORIZATION FORM (form effective 7/23/18)

Prior authorization & quantity limit guidelines are on the Pharmacy Services website: <http://www.dhs.pa.gov/provider/pharmacyservices/index.htm>.

PRIOR AUTHORIZATION REQUEST INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	Total # pages: _____	
Name/phone of office contact:		Prescriber name:	
LTC facility contact/phone:		Specialty:	
		NPI:	State license:
BENEFICIARY INFORMATION		Street address:	
Beneficiary name:		Suite #:	City/state/zip:
Beneficiary ID#:	DOB:	Phone:	Fax:

### CLINICAL INFORMATION

Drug:	Strength:	Quantity per fill: _____ to last _____ days
Directions:		Duration: _____ days / 1 mo / 2 mos / 3 mos
Weight (if <21 yrs): _____	Diagnosis ( <i>submit documentation</i> ):	Diagnosis code ( <i>required</i> ):
1. Did the prescriber or prescriber's delegate search the PDMP to review the beneficiary's controlled substance prescription history before issuing this prescription for the requested agent?		<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>
2. Is the beneficiary taking a benzodiazepine? <b><i>Submit beneficiary's current medication list.</i></b>		<input type="checkbox"/> Yes – list: _____ <input type="checkbox"/> No
3. <b><i>Initial requests for all non-preferred medications:</i></b> Does the beneficiary have a history of trial and failure of or contraindication or intolerance to the following preferred short-acting opioid analgesics? <i>Check all that apply.</i>		<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation of trial &amp; failure, contraindications, or intolerances.</i>
<input type="checkbox"/> APAP/codeine tablet or elixir <input type="checkbox"/> morphine IR tablet <input type="checkbox"/> oxycodone/APAP tablet <input type="checkbox"/> hydrocodone/APAP tablet <input type="checkbox"/> morphine solution or concentrate <input type="checkbox"/> tramadol IR tablet <input type="checkbox"/> hydrocodone/ibuprofen tablet <input type="checkbox"/> oxycodone IR tablet		
4. What is the anticipated duration of therapy with opioid analgesics?		Specify duration: _____ <i>Submit documentation.</i>
5. Is the beneficiary being treated for active cancer, sickle cell with crisis, or neonatal abstinence syndrome OR receiving hospice or palliative care services?		<input type="checkbox"/> Yes – <i>Submit documentation and send to DHS.</i> <input type="checkbox"/> No – <b><i>Continue to the next question.</i></b>
6. Check all of the following that apply to the beneficiary. <b><i>Submit detailed medical record documentation for EACH item.</i></b>		
<b>INITIAL requests:</b>		
<input type="checkbox"/> has documentation of a complete physical exam, including diagnostic testing/imaging results, and pain assessment (cause, severity, location, etc)		
<input type="checkbox"/> has tried or cannot try non-drug pain management modalities (eg, behavioral, cognitive, physical, and/or supportive therapies)		
<input type="checkbox"/> has tried or cannot try non-opioid drugs for the treatment of pain – check drugs tried: <input type="checkbox"/> acetaminophen <input type="checkbox"/> NSAIDs <input type="checkbox"/> other: _____		
<input type="checkbox"/> the requested opioid medication will be used in combination with tolerated non-drug therapies and non-opioid medications		
<input type="checkbox"/> was assessed for the potential risk of misuse, abuse, and addiction based on family and social history obtained by prescriber		
<input type="checkbox"/> was counseled regarding potential side effects of opioids including risk of misuse, abuse, addiction (if <21 yo, parent/guardian may be counseled)		
<input type="checkbox"/> was assessed for recent (within the past 60 days) opioid use		
<input type="checkbox"/> was evaluated for risk factors for opioid-related harm		
<input type="checkbox"/> <i>if identified to be at high risk for opioid-related harm</i> , the prescriber considered prescribing naloxone		
<input type="checkbox"/> has a recent UDS testing for illicit and licit substances of abuse (with specific testing for oxycodone, fentanyl, tramadol, and carisoprodol)		
<b>RENEWAL requests:</b>		
<input type="checkbox"/> experienced an improvement in pain control and level of functioning while on the requested agent		
<input type="checkbox"/> the requested opioid medication will be used in combination with tolerated non-drug therapies and non-opioid medications		
<input type="checkbox"/> is being monitored by the prescriber for adverse events and warning signs of serious problems, such as overdose and opioid use disorder		
<input type="checkbox"/> was evaluated for risk factors for opioid-related harm		
<input type="checkbox"/> <i>if identified to be at high risk for opioid-related harm</i> , the prescriber considered prescribing naloxone		
<input type="checkbox"/> has a recent UDS testing for illicit and licit substances of abuse (with specific testing for oxycodone, fentanyl, tramadol, and carisoprodol)		
7. <b>For requests for nasal butorphanol (Stadol)</b> , check all of the following that apply to the beneficiary. <b><i>Submit documentation for EACH item.</i></b>		
<input type="checkbox"/> the beneficiary is opioid-tolerant (names and dosages of current opioid regimen)		
<input type="checkbox"/> <i>if being treated for migraine</i> , has a history of trial & failure of or contraindication or intolerance to abortive (triptans) & preventive medications		

**PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION**

Prescriber Signature:	Date:
-----------------------	-------

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.